|
Volume 1 Issue 2
|
|
Comment |
|
|
Direct-to-consumer genetic tests: beyond medical regulation?
David Magnus, Mildred K Cho, Robert Cook-Deegan Genome Med 2009, 1:17 (2 February 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
Editor’s summary
Personalized genomic tests provide a large amount of data but, because disease associations are weak for the vast majority of genetic loci, their interpretation remains problematic, raising questions over the need for stronger government regulation.
|
|
|
From association to causality: the new frontier for complex traits
Nicholas Katsanis Genome Medicine 2009, 1:23 (25 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
As genome-wide association studies rarely lead to the identification of causal alleles and therefore to the mechanisms that underlie disease; further efforts to evaluate the physiological impact of variation on gene function are needed.
|
|
|
Ancestry in translational genomic medicine: handle with care
David Gurwitz, Jeantine E Lunshof Genome Medicine 2009, 1:24 (25 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
While personalized decision-making requires the combination of information about the population subgroup a person belongs to with information about the particular individual, genetic evidence should not be used to support policy guidelines that block access of individuals to healthcare based on ancestry.
|
|
|
Genomic medicine: considerations for health professionals and the public
Denise Avard, Bartha Knoppers Genome Medicine 2009, 1:25 (25 February 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
Editor’s summary
As advances in genomic medicine continue, the healthcare community must better understand how to incorporate genomics into delivery of care and must better communicate the risks and challenges of genomic information to the public.
|
|
|
The cycle of genome-directed medicine
Janet A Buchanan, Andrew R Carson, David Chitayat, David Malkin, M Stephen Meyn, Peter N Ray, Cheryl Shuman, Rosanna Weksberg, Stephen W Scherer Genome Medicine 2009, 1:16 (2 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
Medical infrastructure needs to adapt to the dramatic pace of technology development in order for the cycle of genome-directed medicine to be complete.
|
|
|
Musings on genome medicine: abuse of genetic tests
David G Nathan, Stuart H Orkin Genome Medicine 2009, 1:18 (16 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
Developments in prenatal diagnostic testing for serious disorders have huge potential for medicine and public health, but the recent New York Times report of a gene test for athletic potential raises serious ethical questions.
|
|
Review |
|
|
Genome-wide association studies are coming for human infectious diseases
Sonia Davila, Martin L Hibberd Genome Medicine 2009, 1:19 (10 February 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
Editor’s summary
The application of genome-wide association studies to human infectious diseases holds promise for the identification of polymorphisms affecting a large proportion of the population, and thus for improved prognosis and treatment.
|
|
|
A new, effective and high-yield approach for identifying liver tumor suppressors
Esra Olgun, Lewis R Roberts Genome Medicine 2009, 1:26 (26 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
The combination of integrated cancer genomic analysis, RNAi technology and cancer-susceptible mouse models to discover and validate tumor suppressor genes provides novel insights into the development of hepatocellular carcinoma.
|
|
|
Genome-based prediction of common diseases: methodological considerations for future research
A Cecile JW Janssens, Cornelia M van Duijn Genome Medicine 2009, 1:20 (18 February 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
Editor’s summary
A framework for the design and analysis of studies aiming to evaluate the clinical validity and utility of genetic tests is urgently needed to help identify useful genome-based applications for clinical and public health practice.
|
|
|
Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease
Matthew B Lanktree, Robert A Hegele Genome Medicine 2009, 1:28 (26 February 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
Editor’s summary
The study of gene-gene and gene-environment interactions will provide new insights into the determinants of coronary artery disease, though agreed standards of study design and statistical power, environmental exposure measurement, phenomic characterization and analytical strategies are needed.
|
|
Report |
|
|
Copy number variation and genomic alterations in health and disease
George P Patrinos, Michael B Petersen Genome Medicine 2009, 1:21 (20 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
A report of the first Golden Helix Symposium on copy number variation and genomic alterations in health and disease.
|
|
|
Insights from Keystone: advances in the understanding of epigenetic regulation of the genome
Rebecca C Rancourt, Nico Ruf Genome Medicine 2009, 1:27 (26 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
A report on the Keystone Symposium on Epigenetics, Development and Human Disease, Breckenridge, Colorado, USA, 5-10 January, 2009.
|
|
Correspondence |
|
|
Commercialization, patenting and genomics: researcher perspectives
CJ Murdoch, Timothy Caulfield Genome Medicine 2009, 1:22 (19 February 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
Genomic researchers have divided views regarding the effect of commercialization and patenting on research, and although publication delays and the withholding of data are common, the aggressive enforcement of patents is not.
|
